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assessment (HYVET-COG): a double-blind, placebo 
controlled trial 
Ruth Peters, Nigel Beckett, Francoise Forette, Jaakko Tuomilehto, Robert Clarke, Craig Ritchie, Adam Waldman, Ivan Walton, Ruth Poulter, 
Shuping Ma, Marius Comsa, Lisa Burch, Astrid Fletcher, Christopher Bulpitt, for the HYVET investigators
Background Observational epidemiological studies have shown a positive association between hypertension and risk 
of incident dementia; however, the eﬀ ects of antihypertensive therapy on cognitive function in controlled trials have 
been conﬂ icting, and meta-analyses of the trials have not provided clear evidence of whether antihypertensive 
treatment reduces dementia incidence. The Hypertension in the Very Elderly trial (HYVET) was designed to assess 
the risks and beneﬁ ts of treatment of hypertension in elderly patients and included an assessment of cognitive 
function.
Methods Patients with hypertension (systolic pressure 160–200 mm Hg; diastolic pressure <110 mm Hg) who were 
aged 80 years or older were enrolled in this double-blind, placebo-controlled trial. Participants were randomly assigned 
to receive 1·5 mg slow release indapamide, with the option of 2–4 mg perindopril, or placebo. The target systolic 
blood pressure was 150 mm Hg; the target diastolic blood pressure was 80 mm Hg. Participants had no clinical 
diagnosis of dementia at baseline, and cognitive function was assessed at baseline and annually with the mini-mental 
state examination (MMSE). Possible cases of incident dementia (a fall in the MMSE score to <24 points or a drop of 
three points in 1 year) were assessed by standard diagnostic criteria and expert review. The trial was stopped in 2007 
at the second interim analysis after treatment resulted in a reduction in stroke and total mortality. Analysis was by 
intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00122811.
Findings  3336 HYVET participants had at least one follow-up assessment (mean 2·2 years) and were included: 1687 
participants were randomly assigned to the treatment group and 1649 to the placebo group. Only ﬁ ve reports of 
adverse eﬀ ects were attributed to the medication: three in the placebo group and two in the treatment group. The 
mean decrease in systolic blood pressure between the treatment and placebo groups at 2 years was systolic 
–15 mm Hg, p<0·0001; and diastolic –5·9 mm Hg, p<0·0001. There were 263 incident cases of dementia. The rates 
of incident dementia were 38 per 1000 patient-years in the placebo group and 33 per 1000 patient-years in the treatment 
group. There was no signiﬁ cant diﬀ erence between treatment and placebo groups (hazard ratio [HR] 0·86, 95% CI 
0·67–1·09); however, when these data were combined in a meta-analysis with other placebo-controlled trials of 
antihypertensive treatment, the combined risk ratio favoured treatment  (HR 0·87, 0·76–1·00, p=0·045). 
Interpretation Antihypertensive treatment in elderly patients does not statistically reduce incidence of dementia. This 
negative ﬁ nding might have been due to the short follow-up, owing to the early termination of the trial, or the modest 
eﬀ ect of treatment. Nevertheless, the HYVET ﬁ ndings, when included in a meta-analysis, might support 
antihypertensive treatment to reduce incident dementia. 
Funding The British Heart Foundation; the Institute de Recherches Internationales Servier.
Introduction 
Blood pressure, particularly systolic pressure, rises with 
age, leading to a high prevalence of hypertension in 
older people.1 The prevalence and incidence of dementia 
also rise with age, with an estimated prevalence of 
around 20% in those aged 80 years, which rises to 40% 
at age 90 years.2 High blood pressure in midlife is 
predictive of later dementia3 and has been included in a 
risk score for the prediction of dementia, at least up to 
64 years.4 Low blood pressure is also associated with 
incident dementia,5 although this might be the result of 
the dementia rather than a risk factor.5 The authors of a 
systematic review of the age-dependent relation among 
blood pressure, cognitive function, and dementia 
concluded that high blood pressure in elderly people 
might be a risk factor for dementia.6 The authors of 
another systematic review found that a small reduction 
in blood pressure (<5 mm Hg systolic and <3 mm Hg 
diastolic) was associated with improvements in mini-
mental state examination (MMSE) scores, and that 
lowering blood pressure might reduce the mechanisms 
that contribute to Alzheimer’s disease (AD),7 although, 
in practice, it is diﬃ  cult to distinguish vascular dementia 
from AD.8,9 The beneﬁ ts of lowering blood pressure are 
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supported by the results of a double-blind, placebo-
controlled trial in younger elderly people—the Systolic 
hypertension in Europe (Syst-Eur) trial (≥65 years)—in 
whom the incidence of all dementia was reduced by 50% 
after treatment with a calcium-channel blocker.10 Other 
investigators have not established such a clear answer, 
however, and the authors of a meta-analysis of the results 
from four placebo-controlled trials10–14 calculated a 
summary relative risk of 0·80 (95% CI 0·63–1·02) in 
favour of treatment, although this was not statistically 
signiﬁ cant.11 A Cochrane Review of three trials 
comprising 12 091 hypertensive individuals (mean age 
72·8 years) found no convincing evidence that lowering 
blood pressure prevented dementia or cognitive 
impairment.15 Another meta-analysis included one trial 
in which only 16% of patients were on placebo; no 
diﬀ erence between the two randomised groups was 
found.13
The Hypertension in the Very Elderly Trial (HYVET) was 
designed to assess the relative risks and beneﬁ ts of treating 
hypertension in participants aged 80 years and older and 
includes assessment of cognitive function.16
Antihypertensive treatment in very elderly patients 
might also reduce incident dementia cases. The aim of 
the HYVET-COG substudy of the placebo-controlled, 
double-blind HYVET trial was to assess whether 
treatment of hypertension in patients aged 80 years and 
over would reduce the incidence of dementia, vascular 
dementia, and Alzheimer’s disease.
Methods 
Patients
4761 patients were recruited from hospital-based and 
general-practitioner-based centres in western and 
eastern Europe, China, Tunisia, southeast Asia, and 
Australia, and 3845 patients were randomised into 
HYVET between February, 2001, and October, 2007.
Inclusion criteria were age 80 years or older at the time 
of randomisation and an average sitting systolic 
pressure between 160 mm Hg and 200 mm Hg, a 
standing systolic pressure of 140 mm Hg or higher, and 
a sitting diastolic pressure of less than 110 mm Hg. 
Participants were excluded if they required ongoing 
nursing care, had a condition that would severely limit 
their lifespan, or a clinical diagnosis of dementia. 
Patients gave written, informed consent, and appropriate 
measures were taken, in line with international good 
clinical practice requirements, for patients who were 
not suﬃ  ciently literate. A randomisation code was 
created by a random number seed and transferred to an 
independent interactive voice response system (IVRS) 
before the start of the trial. Patients were randomised 
with the IVRS and stratiﬁ ed by age and sex. Patients 
were treated with 1·5 mg slow release indapamide or 
matching placebo daily, with the option of an additional 
2–4 mg perindopril or matching placebos. The target 
systolic blood pressure was 150 mm Hg, and the target 
diastolic blood pressure was 80 mm Hg. All national 
and local approvals for ethics and regulatory aﬀ airs 
were gained, as required by local and international law, 
before the protocol was started or any amendments 
were made. 
Procedures
All patients had baseline blood pressure measurements 
during the run-in period and before randomisation, and 
their cognitive function was assessed with the MMSE. 
The MMSE was repeated annually, and the scores were 
calculated by the coordinating oﬃ  ce staﬀ  [LB and R Po], 
who were blinded to treatment group. Because the aim 
of the study was to assess incident dementia and 
cognitive decline, participants were only included in the 
analysis if they had at least one follow-up MMSE score, 
so that any change could be assessed. Any participant 
who had a fall in MMSE score to less than 24 or whose 
score fell more than three points in 1 year was 
highlighted for further assessment. Participants with 
possible incident dementia were assessed in accordance 
with the diagnostic statistical manual of mental 
disorders, edition IV (DSM-IV), the ﬁ ndings on a CT 
scan of the brain, and a modiﬁ ed Hachinski ischaemic 
score (MHIS). Full Hachinski ischaemic scores (HIS) 
were used if it was not possible to obtain a CT scan of 
the brain, for example if the patient refused. A committee 
1649 randomly assigned to 
            placebo  
3845 randomised
509 did not meet HYVET-COG inclusion criteria
4761 assessed for eligibility
916 did not meet inclusion criteria
1687 randomly assigned to 1·5 mg 
            indapamide with or without 
            2–4 mg perindopril
1649 analysed
             486 had cognitive decline
                      137 diagnosed with dementia
                        86 with Alzheimer’s disease
                        43 with vascular dementia
                           8 with unclassiﬁable dementia
            1163 without cognitive decline
1687 analysed
             485 had cognitive decline
                      126 diagnosed with dementia
                        78 with Alzheimer’s disease
                        41 with vascular dementia
                           7 with unclassiﬁable dementia
           1202 without cognitive decline
303 discontinued trial
           96 died
              5 lost to follow-up
              1 withdrawn by investigator
              1 code broken
           59 for administrative reasons
         141 declined to continue
343 discontinued trial
         132 died
              5 lost to follow-up
           60 for administrative reasons
        146 declined to continue
Figure 1: Trial proﬁ le 
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(JT, RC, CR, AW, and IW) of experts in either geriatric 
psychiatry, medicine for the elderly, neuroradiology, 
clinical trial research, or epidemiology, who were 
blinded to treatment group, assessed each possible case. 
Diagnosis was reached by consensus: a minimum of 
three of the ﬁ ve committee members had to agree on 
each diagnosis, and the input of at least one member 
who had day-to-day experience of diagnosing dementia 
was needed for each case. This led to two levels of 
classiﬁ cation: participants whose MMSE score fell to 
under 24 points or by more than three points in 1 year 
were classiﬁ ed with cognitive decline; or participants 
were diagnosed with dementia after the committee had 
examined all the diagnostic information. Participants 
who were classiﬁ ed with dementia were, if possible, also 
diagnosed with either AD (on the basis of a smooth 
decline, medial temporal lobe atrophy, data from the 
DSM-IV, and no vascular factors seen on CT or recorded 
in the clinical history) or vascular dementia (on the basis 
of a more stepwise decline, results of the CT scan, MIS 
or HIS scores, and a history of vascular events before or 
during the study). Additional information about 
concomitant medication and comorbid disease or 
disease history was provided to the committee. When 
the patient consented, an additional quality of life 
questionnaire (including the short form [SF] 36 and a 
list of symptoms associated with hypertension and 
hypertensive drugs) was completed; the committee’s 
assessment also included annual clock drawing tests 
and geriatric depression scale score results. All MMSE 
assessments were provided in the local language, and 
the investigators and staﬀ  at the coordinating centre 
were trained to use the instruments and explain the trial 
literature in the local languages. The complete methods 
for the collection of data, assessment of cognitive 
function, and assessments for possible incident 
dementia have been described elsewhere.17 
Statistical analysis
We calculated that data from 8400 patient-years would be 
needed to detect a 33% reduction in incident dementia (all 
diagnosed dementia) at the 5% level of signiﬁ cance and 
85% power (α=0·05, β=0·15). The expected rates of 
incident dementia were 36 per 1000 patient-years in the 
placebo group and 24 per 1000 patient-years in the 
treatment group, with an expected total of 252 incident 
cases. The main trial protocol made provision for interim 
analyses based on a stroke endpoint, which led to the 
termination of the trial earlier than planned.16,17
Because the incidence of dementia is insidious and can 
only be identiﬁ ed during periodical examinations, 
complementary log–log regression are the most 
appropriate analyses. However, for ease of exposition, the 
Treatment 
(n=1687)
Placebo 
(n=1649)
Age (years) 83·5 (3·1) 83·5 (3·1)
Women 1023 (61%) 994 (60%)
Baseline sitting SBP (mm Hg) 173·1 (8·5) 172·9 (8·5)
Baseline standing SBP (mm Hg) 167·9 (10·9) 167·9 (10·9)
BMI (kg per m²) 24·6 (3·8) 24·7 (3·5)
Previous stroke 108 (6%) 108 (7%)
Previous cardiovascular disease 187 (11%) 190 (12%)
Consumer of alcohol 313 (19%) 275 (17%)
Current smoker 101 (6%) 101 (6%)
Median MMSE score 26 (15–30) 26 (15–30)
Data are mean (SD), number (percentage), or median (range). SBP=systolic blood 
pressure. BMI=body mass index. MMSE=mini-mental state examination 
(maximum score=30).
Table 1: Characteristics of patients at baseline by treatment allocation
Participants with at 
least one follow-up 
MMSE (n=3336)
Participants who did not 
meet inclusion criteria for 
HYVET-COG (n=509)
Participants with 
incident cognitive 
decline (n=971)
Participants with no 
incident cognitive 
decline (n=2365)
Participants with 
incident dementia 
(n=263)
Participants with 
no incident 
dementia (n=3073)
Age (years) 83·5 (3·1) 83·3 (3·4) 83·8 (3·3) 83·4 (3·0) 83·5 (3·1) 83·5 (3·1)
Women 2017 (60%) 310 (61%) 608 (63%) 1409 (60%) 158 (60%) 1859 (60%)
Previous stroke 216 (7%) 45 (9%) 65 (7%) 151 (6%) 22 (8%) 194 (6%)
Current smoker 202 (6%) 48 (9%) 55 (6%) 147 (6%) 18 (6%) 184 (7%)
Education
None 915 (27%) 115 (23%) 281 (29%) 634 (27%) 76 (29%) 839 (27%)
Primary 940 (28%) 163 (32%) 267 (27%) 673 (28%) 81 (31%) 859 (28%)
Secondary 961 (29%) 141 (28%) 293 (30%) 668 (28%) 87 (33%) 874 (28%)
Higher 409 (12%) 80 (16%) 96 (10%) 313 (13%) 17 (6%) 392 (13%)
Further 111 (3%) 10 (2%) 34 (4%) 77 (3%) 2 (1%) 109 (4%)
Baseline mean sitting SBP (mm Hg) 173·0 (8·5) 173·1 (8·8) 173·3 (8·4) 172·9 (8·5) 172·8 (8·2) 173·0 (8·5)
Baseline mean standing SBP (mm Hg) 167·8 (10·9) 168·8 (11·8) 168·3 (10·9) 167·6 (10·9) 168·2 (10·6) 167·8 (10·9)
Median MMSE score at baseline 26 (15–30) 26 (1–30) 25 (15–30) 27 (15–30) 26 (16–30) 26 (15–30)
Data are mean (SD), number (percentage) or median (range). SBP=systolic blood pressure. mm Hg=millimetres of mercury. MMSE=mini-mental state examination.
Table 2: Baseline characteristics of patients with and without cognitive decline and dementia 
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usual approach of survival analysis with a Cox proportional 
hazards model was also done with the date of cognitive 
decline and the midpoint between cognitively intact 
performance and cognitive decline (deﬁ ned in accordance 
with the protocol) as the event date. The assumptions of 
the Cox model were tested with a supremum test for the 
cumulative sums of the Martingale-based residuals. 
Although the use of midpoint imputation for event time 
can be associated with bias, the use of intervals of less 
than 2 years might help to mitigate such bias, and 
because many studies present this information, we 
include it for ease of exposition.
Survival was analysed with a Cox proportional hazards 
model. The eﬀ ect of the treatment on patients who had a 
stroke or a history of stroke was also investigated. 
Analyses were intention to treat. All statistical analyses 
were done with SAS version 9.1. 
The trial is registered with ClinicalTrials.gov, number 
NCT00122811.
Role of the funding source
Imperial College was the sponsor of the trial and required 
conﬁ dentially agreements with all committee members 
and investigators. The analysis, interpretation of the data, 
generation of the manuscript and decision to submit for 
publication were carried out independently of the funding 
bodies (the British Heart Foundation and the Institute de 
Recherches Internationales Servier). The primary author 
had full access to all of the data and ﬁ nal responsibility 
for the decision to submit for publication.
Results
The main trial was stopped early because a substantial 
reduction in total mortality and stroke was established at 
the second preplanned interim analysis. Not all patients 
who entered the HYVET trial reached at least 1 year of 
follow-up, as required for the assessment of any change 
in cognitive function. Figure 1 shows the trial proﬁ le. 
Patients’ characteristics were well matched at baseline 
(table 1). Patients were seen at intervals of about 1 year, 
with a mean of 400 days (SD 55·2) between assessments 
(median 386 days [range 214–690]). Table 2 shows 
patients’ baseline characteristics by the presence or 
absence of later incident dementia or cognitive decline. 
Table 3 shows the number of cases and hazard ratios for 
cognitive decline, all dementia, Alzheimer’s disease, and 
vascular dementia. 
Fewer serious adverse events were reported in the 
treatment group (358 vs 448, p=0·0009). Only ﬁ ve of 
these were categorised by the local investigator as being 
due to the trial medication: three in the placebo group 
and two in the treatment group.
1469 of 3336 patients (44%) attended their 2-year follow-
up visit. The mean decrease in systolic blood pressure at 
2 years was 14·6 mm Hg (SD 18·5) on placebo versus 
29·6 mm Hg (15·3) on treatment, diﬀ erence 15 mm Hg; 
p<0·0001. The mean reduction in diastolic blood pressure 
was 7·2 mm Hg (10·5) on placebo versus 13·1 mm Hg 
(9·6) on treatment, diﬀ erence 5·9 mm Hg; p<0·0001. 
The mean change in MMSE score at 2 years was 
–1·1 points (SD 3·9) in the placebo group versus 0·7 points 
(4·0) in the treatment group; p=0·08. Follow-up at 2 years 
was chosen to be as close as possible to the mean follow-
up for the cognitive function and dementia outcomes. The 
results were analysed in two ways: to assess the eﬀ ect of 
lowering blood pressure on diagnosed dementia (mean 
follow-up 2·2 years, 7400 patient-years); and to assess the 
eﬀ ect of lowering blood pressure on cognitive decline 
(mean follow-up 2 years, 6680 patient-years).
All patients with serial MMSE scores were included in 
the analysis, and any records that showed cognitive 
decline were assessed by the committee, irrespective of 
Placebo Treatment Hazard ratio
Cognitive decline* 486 485 0·93 (0·82–1·05)
Alzheimer’s disease 86 78 0·85 (0·63–1·15)
Vascular dementia 43 41 0·87 (0·57–1·34)
All dementia† 137 126 0·86 (0·67–1·09)
Data are number of patients or unadjusted hazard ratio (95% CI). *Deﬁ ned as a fall 
in MMSE score to <24 or a decline of >3 points in 1 year. †Alzheimer’s disease, 
vascular dementia, or other (unclassiﬁ able dementia or classiﬁ ed as a type that is 
not listed above).
Table 3: Eﬀ ects of antihypertensive treatment on incident cognitive 
decline or dementia
Placebo
Active 1·5 mg indapamide (2–4 mg perindopril)
p=0·21; HR 0·86 (95% CI 0·67–1·09)
Number at risk 3336 2948 1681 798 433 294 
Incident cases 0 3 70 151 184 200 
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Figure 2:  Cumulative porportion of patients with dementia by treatment group
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death or other events. At the 1-year follow-up, 297 patients 
(18%) in the placebo group and 270 patients (16%) in the 
treatment  group had MMSE scores indicative of cognitive 
decline. In total, 971 patients were categorised with 
cognitive decline, of which 263 cases of dementia were 
diagnosed. 164 patients were classiﬁ ed as having AD, 
84 as having vascular dementia, and 15 as having a 
dementia type that could not be speciﬁ ed. The rates of all 
incident dementia diagnosed were 38 per 1000 patient-
years in the placebo group and 33 per 1000 patient-years 
in the treatment group. 
Figure 2 shows the unadjusted survival analyses for 
incident dementia. Re-analysis with the midpoint 
between the last cognitively intact performance and the 
ﬁ rst with cognitive decline did not change the results 
(unadjusted HR 0·85 [95% CI 0·67–1·09]). Log–log 
complementary regression analyses resulted in a 
similarly non-signiﬁ cant result and an estimate of 
reduced risk at 11% (95% CI 0·70–1·14). Logistic 
regression analysis showed a similar result. The 
unadjusted HR for cognitive decline was 0·92 (95% CI 
0·81–1·05); log–log complementary regression analyses 
resulted in a similarly non-signiﬁ cant result and an 
estimated 4% reduction in risk. 
The results of log-rank analysis showed that lower 
education, region where recruitment occurred, and age 
had a signiﬁ cant eﬀ ect on decline, whereas sex did not. 
Cox proportional hazard models and log–log 
complementary regression analyses were, therefore, 
adjusted for some education versus no education, age, 
and region where recruitment occurred. The adjusted 
HR (Cox) was 0·85 (95% CI 0·67–1·09) for diagnosed 
dementia and HR (Cox) 0·93 (0·82–1·05) for cognitive 
decline; the adjusted HRs calculated with log–log 
complementary regression were similar. Neither strokes 
that occurred before or during the trial nor previous 
antihypertensive treatment or treatment type before 
recruitment altered the results. Most of the strokes that 
occurred during the HYVET trial were fatal. 
The results of analyses by subtype of dementia were 
not signiﬁ cant, and Cox and log–log complementary 
analyses gave similar results. For AD, the respective rates 
were 20 per 1000 patient-years in the treatment group 
and 23 per 1000 patient-years in the placebo group (HR 
0·85, 95% CI 0·63–1·15. For vascular dementia, the rates 
were 11 per 1000 patient-years in the treatment group and 
12 per 1000 patient-years in the placebo group (HR 0·87, 
0·57–1·34. Repeating the analyses with all patients, 
regardless of whether they had more than one cognitive 
function assessment, did not aﬀ ect the results.
When the HYVET results are combined in a meta-
analysis with the three other placebo-controlled trials of 
antihypertensive treatment that assessed incident 
dementia: Syst-Eur;10 the perindopril protection against 
recurrent stroke study (PROGRESS);12 and the Systolic 
Hypertension in Elderly Patients trial (SHEP),14 the 
pooled ratio was borderline signiﬁ cant (with the random 
eﬀ ects model); relative risk 0·87 (95% CI 0·76–1·00; 
p=0·045), whereas previous meta-analyses had been 
inconclusive.11,15 Figure 3 shows the forest plot of this 
analysis. 
Discussion 
We found a non-signiﬁ cant reduction in cases of incident 
dementia in the treatment group. When combined in a 
meta-analysis of other placebo-controlled, double-blind, 
trials of antihypertensive treatment, there was a signiﬁ cant 
reduction in incident dementia in patients randomised to 
antihypertensive treatment. 
The HYVET trial was stopped earlier than planned 
owing to the results of the second (a priori) interim 
analysis, in which the beneﬁ ts of treatment were shown 
by reductions in mortality, stroke, and heart failure. This 
meant that the mean follow-up to assess incident 
dementia was only 2·2 years (7400 patient-years). The 
power calculation for HYVET-COG was based on a 33% 
reduction in incident dementia in the treatment group 
over 8400 patient-years, with rates of 36 per 1000 patient-
years in the placebo group and 24 per 1000 patient-years 
in the treatment group, with an expectation of 252 cases. 
Although only 7400 patient-years were accrued in the 
actual trial, 263 cases of incident dementia were 
identiﬁ ed, with rates of 38 and 33·2 per 1000 patient-
years in the placebo and treatment groups, respectively. 
The expected reduction of 33% might have been too 
optimistic and was based on the evidence available when 
the trial was designed and recruitment started (1999–
2001): a 50% reduction in incident dementia in younger 
patients (Syst-Eur);10 and a non-signiﬁ cant reduction in 
dementia in the treatment group compared with the 
placebo group (1·6% vs 1·9%), also in younger patients 
(SHEP).14 Our estimates also accounted for the fact that 
HYVET used the same methodology as Syst-Eur and 
included only very elderly patients. The rates of incident 
dementia in the placebo group, however, were close to 
those predicted, and the short follow-up might also have 
had an eﬀ ect. Any eﬀ ect of blood-pressure lowering on 
incident dementia might take time to be seen, and a 
mean of 2·2 years’ follow-up might not have been 
PROGRESS RR12 3051/193 3054/217  0·89 (0·74–1·07)
Syst-Eur RR10 1238/11 1180/21  0·50 (0·25–1·02)
SHEP RR14 2365/37 2371/44  0·84 (0·55–1·30)
HYVET RR 1687/126 1649/137  0·90 (0·71–1·13)
Combined (random)     0·87 (0·76–1·00)
Cochran Q=2·409; p=0·491
Test for overall eﬀect; p=0·045
 Active (N/n) Placebo (N/n) Hazard ratio (95% CI)
0·2 2·01·00·5
Favours treatment Favours control
Figure 3: Forest plot of placebo-controlled trials of antihypertensive treatment that assessed incident 
dementia
N=total participants. n=number with dementia.
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suﬃ  cient, despite the diﬀ erences in blood pressure 
between the treatment and placebo groups. 
A further point that might aﬀ ect these ﬁ ndings is the 
choice of treatment. The investigators in the Syst-Eur 
trial achieved the biggest reduction in cases of incident 
dementia with a calcium-channel blocker, in contrast to 
more modest results with other drug types.10
A ﬁ nal point to consider in all trials is the risk of bias; 
patients with worsening cognitive function might be 
more likely to leave a trial, and if this occurs 
disproportionately in one group, the outcome could be 
an overestimate or underestimate. The absence of a 
signiﬁ cant diﬀ erence between the treatment groups in 
the SHEP trial might have been due to diﬀ erences in 
participation, with individuals in the placebo group being 
more likely to leave the trial.18
Although reducing risk in midlife is likely to have a 
protective eﬀ ect in later life, midlife intervention is not 
always possible. Additionally, a high proportion of the 
population are elderly people with untreated hypertension. 
Our meta-analysis included data from trials of younger 
populations; however, most of these were at least the 
younger elderly. The Study on Cognition and Prognosis 
in the Elderly (SCOPE) trial13 focused on cognitive 
decline; however,  the SCOPE investigators had to change 
their protocol during the study, which resulted in 84% of 
their placebo group taking additional antihypertensive 
medication. For this reason, we chose not to include this 
trial in the meta-analysis and focused only on those trials 
that were placebo-controlled.
In the HYVET trial, the number of cases of cognitive 
decline were similar in the two groups. This may be due 
to the higher variability of performance on cognitive tests 
or the speciﬁ city of the MMSE in this patient population. 
Although a history of stroke at baseline independently 
predicted incident dementia, inclusion of this covariate 
did not alter the hazard ratio for the treatment group. 
Less educated populations were more likely to develop 
incident dementia; however, education patterns were less 
clear for cognitive decline. 
The median baseline MMSE score for all participants in 
the dataset was 26, and this is consistent with the scores 
expected for a very elderly group with diﬀ ering levels of 
education.19 There was no diﬀ erence in baseline MMSE 
score in the patients who developed incident dementia 
and those patients who did not. 
In the Syst-Eur trial10 an open-label phase followed the 
double-blind trial, which provided additional information 
about the eﬀ ect of treatment for hypertension on incident 
dementia. The former treatment group in the Syst-Eur 
trial remained at lower risk for incident dementia than 
the former placebo group did, despite most participants 
in both groups receiving antihypertensive treatment in 
the open-label phase. The HYVET trial is continuing as 
an open-label trial, and cases of incident dementia will 
continue to be assessed. This will enable the HYVET 
results to be re-evalued after a longer follow-up.
In summary, the results of the HYVET trial substudy of 
incident dementia and cognitive decline are in line with 
research done in younger age groups. The HYVET results 
provide some support for the treatment of very elderly 
people with hypertension to reduce incident dementia, 
particularly when this is achieved with a relatively short 
follow-up; however, the results for incident cognitive 
decline were inconclusive. The meta-analysis of HYVET 
and three similar trials showed that the reduction in the 
risk of dementia associated with lowering blood pressure 
might be clinically signiﬁ cant.
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